Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens:: role of 5-HT2A and α1-adrenoceptor antagonism

被引:33
作者
Marcus, MM [1 ]
Nomikos, GG [1 ]
Svensson, TH [1 ]
机构
[1] Karolinska Inst, Dept Physiol & Pharmacol, Sect Neuropsychopharmacol, S-17177 Stockholm, Sweden
关键词
nucleus accumbens; core; shell; in vivo voltammetry; dopamine; antipsychotic drugs;
D O I
10.1016/S0924-977X(00)00077-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The effects of acute intravenous administration of several new, atypical antipsychotic drugs (APDs): olanzapine (0.05 and 1.0 mg/kg), sertindole (0.1 and 1.0 mg/kg) and quetiapine (0.25 and 2.5 mg/kg), a selective 5-HT2A receptor antagonist, M100907 (0.03 and 0.3 mg/kg), and an alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg), on regional dopamine output were examined in the two subdivisions of the nucleus accumbens (NAC), the core and shell, which seem associated with motor control and limbic functions, respectively, by using in vivo differential normal pulse voltammetry in anaesthetised, pargyline-pretreated rats. Both quetiapine and sertindole, in the two doses used, caused a more pronounced dopamine release in the shell than in the core region of the NAC. In contrast, the low dose of olanzapine increased dopamine output almost to the same extent in both regions, whereas the high dose increased dopamine output to a greater extent in the core. M100907 selectively increased dopamine output in the shell. Also, prazosin significantly increased dopamine output in the shell, but not in the core. The results indicate that both 5-HT2A and alpha(1)-adrenoceptor antagonism may play an important role in the preferential effect of atypical APDs on dopamine output in the shell versus the core of the NAC. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:245 / 253
页数:9
相关论文
共 58 条
[1]  
ADIDARGHAM A, 1997, J NEUROPSYCHIATRY CL, V9, P1
[2]  
ANDERSSON JL, 1994, N-S ARCH PHARMACOL, V349, P236
[3]   Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].
Beasley, CM ;
Sanger, T ;
Satterlee, W ;
Tollefson, G ;
Tran, P ;
Hamilton, S ;
Green, A ;
Dott, S ;
Pfister, G ;
Roxas, L ;
Small, J ;
Thomas, M ;
Ames, D ;
Schooler, N ;
Baker, R ;
Levine, R ;
Fabre, L ;
Friedel, R ;
Safferman, A ;
Lieberman, J ;
Stahl, S .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167
[4]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[5]   ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia [J].
Borison, RL ;
Arvanitis, LA ;
Miller, BG ;
Alphs, LD ;
Carman, JS ;
Diamond, B ;
Gewirtz, G ;
Hamner, MB ;
Hirshfield, R ;
McEvoy, JP ;
Mukherjee, S ;
Nasrallah, HA ;
Oxenkrug, G ;
Ryan, W ;
Smith, N ;
Tamminga, C .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (02) :158-169
[6]   Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method [J].
Breier, A ;
Su, TP ;
Saunders, R ;
Carson, RE ;
Kolachana, BS ;
de Bartolomeis, A ;
Weinberger, DR ;
Weisenfeld, N ;
Malhotra, AK ;
Eckelman, WC ;
Pickar, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) :2569-2574
[7]   THE PATTERNS OF AFFERENT INNERVATION OF THE CORE AND SHELL IN THE ACCUMBENS PART OF THE RAT VENTRAL STRIATUM - IMMUNOHISTOCHEMICAL DETECTION OF RETROGRADELY TRANSPORTED FLUOROGOLD [J].
BROG, JS ;
SALYAPONGSE, A ;
DEUTCH, AY ;
ZAHM, DS .
JOURNAL OF COMPARATIVE NEUROLOGY, 1993, 338 (02) :255-278
[8]   Radioreceptor binding profile of the atypical antipsychotic olanzapine [J].
Bymaster, FP ;
Calligaro, DO ;
Falcone, JF ;
Marsh, RD ;
Moore, NA ;
Tye, NC ;
Seeman, P ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :87-96
[9]   COMPETITIVE ANTAGONISM OF SEROTONIN (5-HT)(2C) AND 5-HT2A RECEPTOR-MEDIATED PHOSPHOINOSITIDE (PI) TURNOVER BY CLOZAPINE IN THE RAT - A COMPARISON TO OTHER ANTIPSYCHOTICS [J].
CANTON, H ;
VERRIELE, L ;
MILLAN, MJ .
NEUROSCIENCE LETTERS, 1994, 181 (1-2) :65-68
[10]   CENTRAL SYMPATHOMIMETIC ACTIVITY OF (+)-5-METHYL-10,11-DIHYDRO-5H-DIBENZO [A,D]CYCLOHEPTEN-5, 10-IMINE (MK-801), A SUBSTANCE WITH POTENT ANTICONVULSANT, CENTRAL SYMPATHOMIMETIC, AND APPARENT ANXIOLYTIC PROPERTIES [J].
CLINESCHMIDT, BV ;
MARTIN, GE ;
BUNTING, PR ;
PAPP, NL .
DRUG DEVELOPMENT RESEARCH, 1982, 2 (02) :135-145